Takeda to cut 1,000 U.S. jobs and close San Diego hub

Japanese drugmaker streamlines operations as ADHD therapy patent expires

20240802N Takeda

Takeda Pharmaceuticals' profit margin has fallen after the patent expired for Vyvanse, an ADHD drug. © Reuters

HINAKO BANNO and TAITO KUROSE, Nikkei staff writers

TOKYO -- Japan's Takeda Pharmaceuticals will cut roughly 1,000 jobs across the U.S., including by shuttering down its research and development hub in San Diego, Nikkei learned Friday.

Takeda opened the San Diego facility in 2019 with an eye on the city's thriving biotech startup scene. The hub is now slated to close by the end of September, according to paperwork filed with the state of California under the Worker Adjustment and Retraining Notification Act.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.